Perspective Therapeutics, Inc. announced that its Phase 1/2a clinical trial for [212Pb]VMT-α-NET is moving into Cohort 3, administering a higher fixed dose of 6 mCi for patients with unresectable or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback